# Study of AMV564 in Patients With AML

> **NCT03144245** · PHASE1 · COMPLETED · sponsor: **Amphivena Therapeutics, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** AMV564
- **COMBINATION_PRODUCT:** AMV564 in combination with pembrolizumab

## Key facts

- **NCT ID:** NCT03144245
- **Lead sponsor:** Amphivena Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-20
- **Primary completion:** 2020-07-21
- **Final completion:** 2020-11-05
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03144245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03144245, "Study of AMV564 in Patients With AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03144245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*